The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes

Corrado, Francesco; D’Anna, Rosario; Vieste, Giacoma Di; Giordano, D.; Pintaudi, Basilio; Santamaria, Angelo; Benedetto, A. Di

doi:10.1111/j.1464-5491.2011.03284.x

Cited by 140 publications

(114 citation statements)

References 20 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…Araştırma sonunda MI+FA alan grupta açlık kan glukozu, insülin düzeyi ve insülin direncinin diğer gruba göre daha düşük olduğu bulunmuştur. 28 Emine ELİBOL ve ark.…”

Section: Gestasyonel Di̇abetes Melli̇tusunclassified

Inositol and Women Reproductive Health

Elibol¹,

Akdevelioğlu²

2017

Turkiye Klinikleri J Health Sci

View full text Add to dashboard Cite

show abstract

“…Araştırma sonunda MI+FA alan grupta açlık kan glukozu, insülin düzeyi ve insülin direncinin diğer gruba göre daha düşük olduğu bulunmuştur. 28 Emine ELİBOL ve ark.…”

Section: Gestasyonel Di̇abetes Melli̇tusunclassified

Inositol and Women Reproductive Health

Elibol¹,

Akdevelioğlu²

2017

Turkiye Klinikleri J Health Sci

View full text Add to dashboard Cite

show abstract

“…A legújabb hipotézis szerint a mioinozitol képes javítani az inzulinrezisztenciát. Metabolikus hatása is kedvező, mert csökkenti az LDL-koleszterin-és trigliceridszintet, illetve a HDL-koleszterin-szintet növeli [8]. Az utóbbi egy-két évben több prospektív tanulmány leírta, hogy a GDM gyakorisága csökken PCOS-es, illetve cukorbetegség irányában pozitív családi anamnézisű várandósok esetében, ha a gondozás alatt mio-inozitol étrend-kiegészítésben részesültek [19,20].…”

Section: Táblázatunclassified

“…Ha a napi szükséglet szintje nő (például: PCOS, GDM), vagy a sejtekben alacsony a koncentrációja, az hozzájá-rulhat az inzulinrezisztencia létrejöttéhez [1][2][3][4][5][6][7]. Ezekben az esetekben a mio-inozitol pótlása javíthatja az inzulinérzékenységet [8].…”

unclassified

A mio-inozitol jótékony hatása inzulint igénylő 2-es típusú cukorbetegséghez társuló polycystás ovarium szindrómás várandós terápiájában

Kun

Tornóczky

2017

Orvosi Hetilap

View full text Add to dashboard Cite

A szerzők a mio-inozitol hatását mutatják be egy 2-es típusú diabetes mellitusban szenvedő, inzulinkezelést is igény-lő, egyben polycystás ovarium szindrómás (PCOS) várandósnál. A betegnek korábban inzulinkezelés és metformin adása mellett sem volt egyensúlyban a szénhidrátháztartása, hypoglykaemiás rosszullétei gyakoriak voltak. Mio-inozitol és folsav étrendkiegészítő-adás megkezdésével szénhidrátháztartása javult, két hónap múlva várandós lett. A vá-randósság 19. terhességi hetében inkomplett vetélése zajlott. A magzat kórboncolása során a patológus nem talált fejlődési rendellenességet. E terápia mellett a beteg később újból várandós lett, és 29 hetesen egy koraszülöttnek adott életet. Az esetbemutatás arra kívánja felhívni a figyelmet, hogy a mio-inozitol-tartalmú étrend-kiegészítő haté-konyabbá teheti a cukorbetegség kezelését. Orv. Hetil., 2017, 158(14), 541-545. Kulcsszavak: inzulint igénylő 2-es típusú cukorbetegség, polycystás ovarium szindróma, várandósságThe myo-inositol is beneficial in the therapy of pregnancy with insulindependent type 2 diabetes and polycystic ovary syndromeAuthors would like to demonstrate the beneficial effect of myo-inositol supplementation in a pregnant woman with insulin-dependent type 2 diabetes mellitus and polycystic ovary syndrome. Insulin and metformin treatment could not achieve normalization of glucose homeostasis for 3 years, and hypoglycemic episodes were frequent. Myo-inositol and folic acid supplementation added to the basic treatment resulted in improved glucose levels in 2 months. At this time she became pregnant. During pregnancy serum glucose levels still improved in the next 2 months. The amniotic membrane ruptured at the 19th gestational week, and pregnancy had to be finished. Developmental disturbances were excluded by the pathologist. She became pregnant again and gave birth to a premature male neonate at the 29th gestational week. The aim of the report was to demonstrate that myo-inositol supplementation may improve the efficacy of the therapy in type 2 diabetes mellitus.Keywords: insulin-dependent type 2 diabetes, polycystic ovary syndrome, pregnancy Kun, A., Tornóczky, J. [The myo-inositol is beneficial in the therapy of pregnancy with insulin-dependent type 2 diabetes and polycystic ovary syndrome]. Orv. Hetil., 2017, 158(14), 541-545. ESETISMERTETÉSRövidítések BMI = (body mass index) testtömegindex; FSH = folliculusstimuláló hormon; GADA = glutaminsav-dekarboxiláz-ellenes antitest; GDM = (gestational diabetes mellitus) terhességi cukorbetegség; IAA = inzulin-autoantitestek, ICA = (islet cell antibodies) szigetsejtellenes antitestek; LADA = (latent autoimmun diabetes in adults) latens felnőttkori autoimmun diabetes mellitus; LH = luteinizáló hormon; PCOS = (polycystic ovar syndrome) polycystás ovarium szindróma; SHGB = (sex hormone-binding globulin) nemihormon-kötő szérumfehérje; TSH = (thyroid-stimulating hormone) pajzsmirigyműködést serkentő hormon

show abstract

“…In particular, Corrado et al found a decreased fasting glucose and insulin in GDM patients treated by 4 g MI daily [16]. Afterwards, D'Anna et al have published the first report about the effect of MI on GDM occurrence in PCOS infertile women [17].…”

Section: Inositol As a Therapeutic Option To Prevent Gdmmentioning

confidence: 99%

“…Considering the insulin-mimetic effect of inositol supplementation in several animal models of insulin resistance [12][13][14] and in women with polycystic ovary syndrome (PCOS) [15], it has been recently hypothesized and studied its positive on the GDM incidence [16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

The Prevention of Gestational Diabetes

Cagnazzo¹,

Caserta²

2013

J Diabetes Metab

View full text Add to dashboard Cite

The negative impact of the gestational diabetes on the maternal and fetal health is well known and this impact is closely related to gestational age at which the diagnosis is done. Therefore, the use of therapeutic options able to prevent or delay the gestational diabetes occurrence has a positive impact on maternal and neonatal outcomes.Physical activity and dietary advice represent the first choice and they are the most studied as well. They represent a non-pharmacological option and have a positive impact on insulin resistance although they do not seem to prevent the gestational diabetes onset.The preconceptional use of metformin in women with polycystic ovary syndrome protects the pancreatic beta cell reserve preventing or delaying the occurrence of gestational diabetes. However, there are also doubts on the drug safety in pregnancy since it completely crosses the placenta.From this point of view, the inositol could represent an excellent alternative.Its role as insulin sensitizing agent is well documented on improving both the hormonal and reproductive parameters. However, the studies on its preconceptional use in preventing gestational diabetes are too limited though the first results are extremely encouraging.

show abstract

The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes

Abstract: Myoinositol improves insulin resistance in patients with gestational diabetes.

Cited by 140 publications

References 20 publications

Inositol and Women Reproductive Health

Inositol and Women Reproductive Health

A mio-inozitol jótékony hatása inzulint igénylő 2-es típusú cukorbetegséghez társuló polycystás ovarium szindrómás várandós terápiájában

The Prevention of Gestational Diabetes

Contact Info

Product

Resources

About